730例慢性阻塞性肺病患者治疗现状的调查
发布时间：2018-11-20 12:56
【摘要】：目的：通过730例COPD稳定期患者的临床症状、急性加重病史、肺功能和药物治疗进行调查及综合评估，分析A、B、C、D四类临床特征患者的治疗现状与2011版GOLD推荐选用药物的差距。 方法：2010年11月至2011年10月对到山西省22家大中型医院就诊的COPD稳定期患者进行问卷调查。调查内容包括患者的一般情况、COPD评估测试(CAT)、过去的急性加重病史、稳定期用药情况、肺功能结果。根据2011年《慢性阻塞性肺疾病全球防治创议》GOLD（GlobalInitiativeforChronicObstructiveLungDisease）新的修订版的分类方法分为A、B、C、D四类不同临床特征的患者群，比较这四类患者治疗情况和GOLD推荐的治疗方案的差异。采用的是描述统计方法进行统计学分析。 结果：1、共收调查问卷760份，有效问卷730份。2、730例COPD患者年龄在42～91岁之间，平均年龄65.58±9.64岁，其中男性占80.14%（585/730），女性占19.86%（145/730），男女比例4.03:1。3、A、B、C、D四类患者分别占5.07%（37/730）、41.78%（305/730）、4.93%（36/730）、48.22%（352/730）。4、使用药物情况与2011版GOLD推荐的首选药物符合率分别为：A类13.51%（5/37）、B类5.25%（16/305）、C类8.33%（3/36）、D类9.09%（32/352）。5、平常使用药物控制症状的患者占98.2%（717/730），其中遵医嘱用药的患者占35.62%，按需使用药物的患者占44.79%。6、其中在使用药物中氨茶碱治疗者占首位63.61%（456/717），其次是使用祛痰剂30.68%（220/717），使用短效β2受体激动剂占23.85%（171/717），使用抗生素分别占19.94%（143/717），使用糖皮质激素患者占18.13%（130/717），，使用抗胆碱能受体占8.93%（64/717）、吸入型糖皮质激素联合β2受体激动剂（9.76%，70/717）。 结论：COPD患者多见于老年人，稳定期COPD患者实际用药与GOLD有较大差异，药物治疗欠规范，联合吸入糖皮质激素和长效β2受体激动剂、单独吸入激素以及抗胆碱能受体相当低。症状驱动式、间断、按需治疗患者多。需加强对患者的健康宣教及稳定期患者规范化治疗。
[Abstract]:Objective: to investigate and evaluate the clinical symptoms, acute exacerbation history, pulmonary function and drug therapy of 730 patients with stable COPD. The current treatment status of D-4 patients with clinical characteristics is different from that recommended by GOLD version 2011. Methods: from November 2010 to October 2011, a questionnaire survey was conducted among the stable COPD patients in 22 large and medium hospitals in Shanxi Province. The survey included general information of patients, COPD assessment of (CAT), 's past history of acute exacerbation, stable use of drugs, and pulmonary function results. According to the new revised classification of the 2011 Global Initiative for the Prevention and treatment of chronic obstructive Pulmonary Disease (GOLD (GlobalInitiativeforChronicObstructiveLungDisease), there are four groups of patients with different clinical characteristics. To compare the differences between the four groups of patients and the treatment regimen recommended by GOLD. A descriptive statistical method was used for statistical analysis. Results: 1. There were 730 valid questionnaires and 730 valid questionnaires. The average age of 2730 COPD patients was 65.58 卤9.64 years old. The male was 80.14% (585 / 730), the female was 19.86% (145 / 730), the average age was 65.58 卤9.64 years old. The ratio of men to women was 4.03: 1.3% (3.03%), 4.93% (36 / 730), 48.22% (352,730), respectively, in 5.07% (37 / 730), 41.78% (305 / 730), 4.93% (36 / 730), 48.22% (352 / 730). The coincident rates of drug use with those recommended by GOLD 2011 were 13.51% (5.25%) for A / 37), B (8.33% for 16 / 305), C) and 9.09% (32 / 352) for 3 / 36), D, respectively. 98.2% of patients (717 / 730) used drugs to control their symptoms, of which 35.62 were prescribed by doctors and 44.79.6. Among them, aminophylline treatment accounted for 63.61% (456 / 717), followed by expectorant 30.68% (220 / 717), short-term 尾 _ 2 agonist 23.85% (171 / 717), aminophylline treatment accounted for 63.61% (456 / 717), followed by expectorant 30.68% (220 / 717). Antibiotics accounted for 19.94% (143 / 717), glucocorticoids 18.13% (130 / 717), anticholinergic receptors 8.93% (64 / 717), and glucocorticoids 18.13% (130 / 717), respectively. Inhaled glucocorticoids combined with 尾 2 receptor agonists (9.76% 70 / 717). Conclusion: COPD patients are more commonly seen in the elderly. The actual drug use in stable COPD patients is different from that in GOLD patients, and the drug treatment is not standardized. The combination of inhaling glucocorticoid and long-acting 尾 _ 2 agonist, inhaling hormone alone and anticholinergic receptor is quite low. Symptom-driven, intermittent, on-demand treatment of more patients. Health education and standardized treatment should be strengthened.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R563.9
本文编号：2344974
[Abstract]:Objective: to investigate and evaluate the clinical symptoms, acute exacerbation history, pulmonary function and drug therapy of 730 patients with stable COPD. The current treatment status of D-4 patients with clinical characteristics is different from that recommended by GOLD version 2011. Methods: from November 2010 to October 2011, a questionnaire survey was conducted among the stable COPD patients in 22 large and medium hospitals in Shanxi Province. The survey included general information of patients, COPD assessment of (CAT), 's past history of acute exacerbation, stable use of drugs, and pulmonary function results. According to the new revised classification of the 2011 Global Initiative for the Prevention and treatment of chronic obstructive Pulmonary Disease (GOLD (GlobalInitiativeforChronicObstructiveLungDisease), there are four groups of patients with different clinical characteristics. To compare the differences between the four groups of patients and the treatment regimen recommended by GOLD. A descriptive statistical method was used for statistical analysis. Results: 1. There were 730 valid questionnaires and 730 valid questionnaires. The average age of 2730 COPD patients was 65.58 卤9.64 years old. The male was 80.14% (585 / 730), the female was 19.86% (145 / 730), the average age was 65.58 卤9.64 years old. The ratio of men to women was 4.03: 1.3% (3.03%), 4.93% (36 / 730), 48.22% (352,730), respectively, in 5.07% (37 / 730), 41.78% (305 / 730), 4.93% (36 / 730), 48.22% (352 / 730). The coincident rates of drug use with those recommended by GOLD 2011 were 13.51% (5.25%) for A / 37), B (8.33% for 16 / 305), C) and 9.09% (32 / 352) for 3 / 36), D, respectively. 98.2% of patients (717 / 730) used drugs to control their symptoms, of which 35.62 were prescribed by doctors and 44.79.6. Among them, aminophylline treatment accounted for 63.61% (456 / 717), followed by expectorant 30.68% (220 / 717), short-term 尾 _ 2 agonist 23.85% (171 / 717), aminophylline treatment accounted for 63.61% (456 / 717), followed by expectorant 30.68% (220 / 717). Antibiotics accounted for 19.94% (143 / 717), glucocorticoids 18.13% (130 / 717), anticholinergic receptors 8.93% (64 / 717), and glucocorticoids 18.13% (130 / 717), respectively. Inhaled glucocorticoids combined with 尾 2 receptor agonists (9.76% 70 / 717). Conclusion: COPD patients are more commonly seen in the elderly. The actual drug use in stable COPD patients is different from that in GOLD patients, and the drug treatment is not standardized. The combination of inhaling glucocorticoid and long-acting 尾 _ 2 agonist, inhaling hormone alone and anticholinergic receptor is quite low. Symptom-driven, intermittent, on-demand treatment of more patients. Health education and standardized treatment should be strengthened.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R563.9
【参考文献】
相关期刊论文 前8条
1 刘丽;罗如滢;蒋胜华;;糖皮质激素对慢性阻塞性肺疾病急性期的疗效观察[J];南华大学学报(医学版);2008年01期
2 张颖;张涛;;联合吸入糖皮质激素和支气管舒张剂在COPD治疗中的应用进展[J];临床肺科杂志;2009年01期
3 方晓惠,钮善福;沐舒坦针剂治疗呼吸系统疾病疗效观察[J];上海医科大学学报;2000年02期
4 张海琴;李燕芹;秦慧;刘斌;;关于内科医师对慢性阻塞性肺疾病诊疗行为的调查[J];上海医学;2008年11期
5 何权瀛;周新;谢灿茂;梁宗安;陈萍;吴昌归;卢宪中;;中国部分城市稳定期慢性阻塞性肺疾病治疗现况断面调查[J];中国实用内科杂志;2009年04期
6 陆如山，曾刚,缪竞诚，徐兴娣，徐培君，顾冠彬，张云，盛伟华;慢阻肺及肺心病患者细胞免疫功能的改变[J];中国实用内科杂志;1995年04期
7 杨鹤,刘志,于润江;慢性阻塞性肺疾病合并呼吸衰竭患者呼吸驱动与呼吸方式的分析[J];中华结核和呼吸杂志;2002年02期
8 李志平,黄建强,唐可京;713例慢性阻塞性肺疾病若干问题的回顾性研究[J];中华流行病学杂志;2003年08期
本文编号：2344974
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2344974.html
最近更新
教材专著
